Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07047365 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

StatusRecruiting
PhasePhase 3
Started2025-07-25
View on ClinicalTrials.gov ↗

Amendment history

2026-06-02
Study Status, Contacts/Locations v3
Trial sites expanded: 69 → 75 locations
2026-01-29
Study Status, Contacts/Locations v2
Study sites66→69
2025-07-28
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-07→confirmed 2025-07-25
Study sitesdetails revised at 66 of 66 sites
2025-06-24
Original filing
TQB2930 is a HER2 bispecific antibody drug. This study aims to evaluate the efficacy and safety of TQB2930 combined with investigator's choice of chemotherapy versus trastuzumab combined with investigator's choice of chemotherapy in subjects with HER2-positive advanced breast cancer who have received at least two prior lines of anti-HER2 therapy in the advanced station.
Trial Details
NCT Number NCT07047365
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions HER2-positive Advanced Breast Cancer
Enrollment 416 participants
Start Date 2025-07-25
Primary Completion 2028-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-03